Nanjing Leads Biolabs Co.,ltd

This study is testing whether adding an experimental drug called LBL-024 to standard chemotherapy (paclitaxel) works better for women whose ovarian cancer has stopped responding to platinum-based drugs. The trial will enroll about 110 women to first check safety and then compare …

This study is testing a new drug called LBL-024 combined with standard chemotherapy (etoposide and platinum) for people with advanced neuroendocrine carcinoma who haven't had prior systemic treatment. The trial aims to find the safest and most effective dose and see how well the …

This study is testing whether a new drug called LBL-024, when combined with other cancer drugs, can help control advanced liver cancer and bile duct cancer. It will enroll about 140 patients to see if the treatment shrinks tumors and is safe. The trial is in Phase 2, meaning rese…

This study is testing a new drug called LBL-024, given alone or with a standard chemotherapy drug, for people with advanced triple-negative breast cancer that has returned or spread. The main goals are to see if the treatment is safe and if it can shrink tumors or slow the cancer…

This study is testing a new drug called LBL-034 in people with multiple myeloma that has returned or isn't responding to other treatments. The first part aims to find a safe and tolerable dose. The second part will see how well the drug works at shrinking the cancer and keeping i…

This study is testing whether a new drug called LBL-024, when combined with other cancer drugs, is safe and effective for people with advanced esophageal cancer that has spread. It will involve about 110 participants to see if the treatment shrinks tumors and controls the disease…

This is the first human study of an experimental drug called LBL-047 for systemic lupus erythematosus. Researchers will test single injections in healthy volunteers first to check safety, then in people with mild to moderate lupus. The main goal is to find safe dose levels and un…

This study is testing whether combining two immunotherapy drugs—LBL-007 and tislelizumab—is safe and effective for treating various cancers. Researchers will enroll up to 490 adults with solid tumors to determine the best dose and see how well the combination shrinks tumors. The …

This study is testing whether a new drug called LBL-024, when given with other cancer drugs, can help control advanced non-small cell lung cancer. It will involve about 230 patients to see how well the combination shrinks tumors and how safe it is. The main goal is to measure how…

This study is testing new drug LBL-024, both alone and in combination with other medications, for people with advanced melanoma that has spread. Researchers want to see if these treatments can help control the cancer and are safe for patients. The trial will enroll about 200 adul…